Quanterix Reports Q4 Revenue Beat, Increased FY25 Loss, Targets 2026 Cash Flow Breakeven
Summary
Quanterix announced Q4 2025 financial results, exceeding revenue expectations, and provided 2026 guidance targeting cash flow breakeven in the second half, alongside significant progress in Alzheimer's diagnostics.
Key Events
-
Q4 2025 Revenue Beat
Reported $43.9 million in Q4 revenue, a 25% increase year-over-year, exceeding expectations.
-
Increased Full Year 2025 Net Loss
Full year 2025 net loss significantly widened to $107.15 million, or $(2.51) per share, compared to $38.53 million in 2024.
-
2026 Cash Flow Breakeven Target
Company expects to achieve cash flow breakeven in the second half of 2026 and exit the year with approximately $100 million in cash.
-
Alzheimer's Diagnostics Progress
Submitted a 510(k) premarket notification to the FDA for its multi-analyte Alzheimer's blood test and secured an $897 CMS reimbursement rate for its LucentAD Complete test.
Analysis
Quanterix reported a significant net loss for the full year 2025, consistent with the concurrent 10-K filing, but highlighted a strong fourth quarter revenue beat and substantial progress on cost synergies. The company's guidance for 2026, particularly the expectation to achieve cash flow breakeven in the second half and exit the year with approximately $100 million in cash, provides a critical outlook for investors. Strategic advancements in Alzheimer's diagnostics, including an FDA 510(k) submission and CMS reimbursement rate approval, further support the company's long-term growth strategy despite the challenging 2025 financial performance.
At the time of this filing, QTRX was trading at $6.23 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $295.7M. The 52-week trading range was $4.05 to $8.77. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.